# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-26-010119
**Filing Date:** 2026-3
**Character Count:** 6056
**Document Hash:** e0c15fe0b48105ed9f191da807fcb371
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-010119.hdr.sgml**: 20260313

**ACCESSION NUMBER**: 0001493152-26-010119

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260313

**DATE AS OF CHANGE**: 20260313

**EFFECTIVENESS DATE**: 20260313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-200834
- **FILM NUMBER:** 26753639

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**Registration No. 333-200834**

**As filed with the Securities and Exchange Commission on March 13, 2026**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**COSCIENS Biopharma Inc.**

**(f/k/a Aeterna Zentaris Inc.)**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Canada** | **N/A** |
| (State or other jurisdiction<br> of incorporation or organization) | (I.R.S. Employer<br> Identification Number) |

---

**c/o Borden Ladner Gervais, LLP**

**22 Adelaide St. West, Suite 3409**

**Bay Adelaide Centre, East Tower**

**Toronto ON M5H YE3, Canada**

(Address of Principal Executive Offices)

**Second Amended and Restated Stock Option Plan**

(Full Title of the Plan)

**Giuliano La Fratta**

**Chief Financial Officer**

**COSCIENS Biopharma Inc.** 

**c/o** **Borden Ladner Gervais, LLP**

**22 Adelaide St. West, Suite 3409**

**Bay Adelaide Centre, East Tower**

**Toronto ON M5H YE3, Canada**

**Telephone: (843) 900-3223** 

(Name, Address and Telephone Number of Agent for Service)

*Copies to:*

 

**Scott R. Saks, Esq.**

**Norton Rose Fulbright US LLP**

**1301 Avenue of the Americas**

**New York, New York 10019-6022**

**Telephone: (212) 318-3151**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

**DEREGISTRATION OF SECURITIES**

On December 10, 2014, COSCIENS Biopharma Inc. (f/k/a Aeterna Zentaris Inc.) (the "Company") filed a Registration Statement on Form S-8 (File No. 333-200834) (the "Registration Statement"), registering 7,468,035 common shares, no par value per share, of the Company ("Shares"), for issuance under the Second Amended and Restated Stock Option Plan of the Company (the "Plan"), consisting of (i) 1,722,999 Shares reserved for issuance upon the exercise of options previously granted under the Plan and (ii) 5,745,036 Shares issuable upon the exercise of options issuable under the Plan. All Shares of the Company carry rights to purchase additional Shares pursuant to a Shareholder Rights Plan Agreement between the Company and Computershare Trust Company of Canada. Such purchase rights are attached to and trade with the Shares. The Registration Statement also registered the purchase rights attached to the Shares registered under the Registration Statement.

This Post-Effective Amendment No. 1 to Form S-8 relates to the Registration Statement. The Company has terminated the offering of the securities pursuant to the Registration Statement in the United States. In accordance with undertakings contained in the Registration Statement to remove by means of a post-effective amendment any securities that remain unsold at the termination of the offering, this Post-Effective Amendment No. 1 hereby terminates the effectiveness of the Registration Statement and removes from registration any and all of such securities registered and remaining unsold under the Registration Statement as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, and Rule 478 thereunder, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Montreal, Province of Quebec, on this 13<sup>th</sup> day of March, 2026.

---

| | |
|:---|:---|
| **COSCIENS BIOPHARMA INC.** | **COSCIENS BIOPHARMA INC.** |
| By: | */s/ Giuliano La Fratta* |
| Name: | Giuliano La Fratta |
| Title: | Chief Financial Officer |

---

Note: No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statement in reliance upon Rule 478 promulgated under the Securities Act of 1933, as amended.